SPECTRUM PHARMACEUTICALS INC SPPI Cash Flow

Spectrum pharmaceuticals inc (SPPI)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash Flows From Operating Activities:
Cash Flows From Operating Activities:
Loss from continuing operations
-40,617	-40,226	-26,557	-28,757	-39,846	-53,255	-69,172	14,893	-19,172	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Income from discontinued operations, net of income taxes (Note 10)
45	1,072	572	466	20,587	3,306	454	-1,151	3,356	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net loss
-40,572	-39,154	-25,985	-28,291	-19,259	-49,949	-68,718	13,742	-15,816	-29,498	-18,293	-20,851	-23,547	-18,700	-17,454	-24,295	-9,321	-6,010	-18,724	-2,346	-25,562	-2,976	-11,539	-3,563	-27,641	-39,372	-7,605	-9,722	-5,435	7,490	22,099	18,070	46,542	9,695	20,255	7,204	12,777
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,100	1,000	979	9,321	3,075	3,075	3,075	3,075	3,075	3,075	3,075	3,075
Depreciation and amortization
140	133	87	69	1,331	7,409	7,007	6,998	6,995	7,007	7,004	6,979	6,982	6,999	7,013	6,472	6,008	10,634	7,106	7,112	7,017	6,660	6,513	6,199	5,980	5,847	5,477	5,426	5,346	5,529	2,671	2,375	1,668	1,659	1,511	1,328	1,152
Deferred income tax benefit
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1,805	-8,125	-23,368	-	-	-	-
Stock-based compensation (Note 4)
5,275	4,633	4,186	5,019	8,000	4,286	3,986	4,733	4,478	4,938	2,994	3,487	3,720	3,916	3,150	3,427	3,177	5,451	2,500	3,528	2,462	3,220	3,064	2,954	2,571	3,761	2,991	2,924	2,747	5,460	3,327	3,082	3,015	7,021	4,336	6,816	4,064
Recognized gain on Commercial Product Portfolio Transaction (Note 10)
0	1,117	-193	0	33,644	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of operating leases (Note 8(a))
381	-	439	365	509	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of discount on investments in debt securities, recorded to interest income (Note 3(a))
29	-143	17	331	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Realized gain on mutual funds
189	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Impairment of intangible assets (Note 3(g))
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	7,160	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of Allos deferred development costs and deferred payment contingency (Note 16)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-6	-	-	-	-	-	-	-	-
Research and development expense recognized for the value of common stock issued in connection with QAPZOLA (Note 17(b)(x)) and ROLONTIS (Note 17(b)(xiii)) milestone achievements
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	2,308	111	0	0	0	0	0	0	0	7,790	-	-	-	-	-	-	-	-	-	-	-	-
Income tax recognition on unrealized gain on available-for-sale securities
-	-	-	-	-	-	-	-	-	-	-2,068	960	-960	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized loss on CASI stock holdings (Note 3(a) and Note 7)
-10,238	9,751	2,013	425	-12,183	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Provision for inventory obsolescence
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	85	349	88	-	-	-	-
Unrealized gain from transactions denominated in foreign currency
22	1,464	0	4	1	-14	-7	-18	8	5,219	3	4	11	-2	158	11	-14	592	3,557	-2,864	-1,128	-1,564	-3,863	-970	364	-547	-21	305	-959	-	-	-	-	-	-	-	-
Change in deferred tax liabilities
0	2,947	0	0	-1,469	-1,936	0	0	9	4,803	27	53	74	-64	-91	-19	70	121	-95	-55	239	-423	-781	-353	955	-	-	-	-	-	-	-	-	-	-	-	-
Unrealized loss (gain) on marketable securities (Note 3(a))
-	-	-	-	-	-	-	-	10,196	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of contingent consideration (Note 8(b))
0	-1,478	0	0	1,478	2,648	-1,200	192	291	1,654	2,942	97	197	-	-78	285	1,042	-	-81	146	500	-	181	1,005	724	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of deferred financing costs on 2018 Convertible Notes, recorded to interest expense (Note 9)
-	-	-	-	-	-1,338	479	546	533	-3,669	1,442	1,413	1,381	1,464	1,446	1,415	1,385	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Bad debt expense (recovery)
-	-	-	-	-	-	-	-	-	-	-	-	-	72	0	1	-16	-11	11	-44	44	-39	-18	42	-70	68	15	21	23	-56	-41	-89	58	56	-102	186	105
Research and development expense for the value of stock issued to TopoTarget in connection with milestone achievement (Note 13)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13,567	10,460	11,883	-	-	-	-	-	-	-	-
Change in fair value of common stock warrants issued to non-employees
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	2,999	-1,237	-5,250
Accretion of debt discount, recorded to interest expense on 2018 Convertible Notes (Note 14)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,270	-	1,224	1,185	1,147	-	-	-	-	-	-	-	-	-	-	-	-
Write off of Deferred Debt Issuance Cost
-	-	-	-	-	-	54	63	61	-	170	155	166	175	176	174	171	169	166	165	162	156	135	177	131	-	-	-	-	-	-	-	-	-	-	-	-
Change in cash surrender value of corporate-owned life insurance policy
-	-	-	-	-	-	-	-	-	152	113	49	104	137	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in operating assets and liabilities:
Accounts receivable, net
0	-61	-2,045	-12,400	-14,914	408	1,835	-5,670	583	-5,551	-4,248	2,415	-310	-2,546	8,136	15,090	-11,186	-17,708	6,429	-27,102	-1,864	11,115	3,325	2,777	4,454	-5,372	2,559	12,989	-52,735	1,170	-771	29,370	3,735	3,993	1,193	-5,340	31,051
Other receivables
-762	1,803	-2,467	2,759	3,776	-1,431	2,221	19	762	-3,751	1,387	-1,489	190	-1,324	117	-8,188	2,500	-991	5,251	358	2,399	-3,879	-2,454	3,616	647	-	-	-	-	-	-	-	-	-	-	-	-
Inventories
0	0	0	0	2,037	-528	-2,046	-159	-657	-3,764	-126	-1,632	1,204	-968	2,090	1,937	2,741	264	-1,729	-277	-121	-677	-938	-2,038	-600	-1,123	-1,281	-1,306	2,140	-4,022	3,131	-824	-1,815	477	886	2,779	2,386
Prepaid expenses and other assets
960	-2,532	1,841	3,676	-512	1,280	3,529	967	-2,134	7,109	-1,411	643	-204	1,227	-251	601	-1,154	313	1,272	-703	-436	-574	1,095	-14,287	14,484	-2,834	-2,498	4,864	827	494	-10,927	376	574	7,431	-304	96	-108
Deferred tax assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-90	2	235	-203	-1,449	-74	2	-43,268	3,977	727	5,312	-	-	-	-	-	-	-	-
Other assets
-823	-240	341	107	980	-120	-1,439	-5,144	1,693	-1,390	680	453	-1,316	-52	721	550	824	333	-1,593	2,587	404	-642	11,930	1,012	861	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and other accrued liabilities
-3,919	-432	-1,899	-19,287	-14,151	12,569	7,753	-1,003	-7,207	9,413	-6,473	7,788	-4,269	2,562	1,758	721	-9,074	-22,660	7,414	-10,274	-2,778	-16,660	32,623	-2,235	-8,424	2,207	-14,609	3,105	-14,600	-2,580	-9,791	34,562	1,847	9,361	-1,327	11,939	-4,262
Accrued payroll and benefits
-3,118	1,210	1,214	93	-4,685	2,109	2,797	1,546	-5,860	1,623	1,394	1,070	-3,807	1,241	1,246	1,944	-3,641	1,053	1,359	1,411	-4,056	1,603	1,714	741	-2,464	-899	1,796	643	-1,115	-10,222	-1,221	484	1,233	-1,850	822	562	-1,059
FOLOTYN development liability
0	0	0	0	-4	-119	-75	-92	-103	-40	-137	-208	-359	-1,030	-223	-128	-175	285	-89	-630	-666	-617	-786	-318	-236	-5,056	1,491	-422	-1,930	1,630	-186	-146	1,078	-941	2,398	35	2,027
Other long-term liabilities
-2,153	813	391	819	1,024	-346	246	-789	325	-4,912	676	577	270	832	111	551	659	481	-31	50	855	303	77	286	-542	-	-	224	519	-	-	-	-	-	-	-	-
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-296	-1,568	966	1,385	-3,768	-3,870	2,890	-10,086	7,555	0	9,926	-425	302	-	-	-	-	-	-	-	-	-	-	-	-
Deferred revenue and other credits
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	246	305	314	-	-42	-54	-1
Net cash used in operating activities
-33,343	-31,192	-27,090	-36,294	-40,055	-12,310	-10,846	-12,502	-26,745	-12,898	-6,503	673	-20,127	-3,365	-12,951	-17,060	-7,083	3,101	-9,345	18,275	-5,287	11,016	9,687	15,659	-39,989	7,920	-13,450	-18,199	21,643	8,097	18,913	18,043	26,906	10,963	20,033	28,643	-16,351
Purchase of equity securities (Note 10)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	17	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash Flows From Investing Activities:
Cash Flows From Investing Activities:
Proceeds from Commercial Product Portfolio Transaction (Note 1(b))
0	-194	0	0	158,765	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from maturities of marketable securities
50,133	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from sale of mutual funds
833	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Sales and maturities of marketable securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,063	13,603	51,676	6,121	-3,901	6,999	5,472	9,685
Purchases of investment securities available-for-sale (Note 3(a))
8,998	72,576	20	127,564	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	44	14,442	7,393	4,551	-4,941	5,996	6,809	9,163
Purchases of mutual funds
1,210	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of property and equipment (Note 3(b))
1,395	348	7,429	927	314	61	0	-6	52	53	245	31	136	17	0	0	61	11	0	134	78	126	203	285	320	34	0	83	44	8	2	210	92	95	39	161	180
Proceeds from redemption of corporate-owned life insurance policy
-	-	-	-	-	0	0	0	4,130	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Redemption of mutual funds
-	-	-	-	-	-	-	-	1	-	0	0	1	-	0	0	1	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchases of available-for-sale securities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	1,090	0	622	-	-	-	-
Net cash provided by investing activities
39,363	-34,133	31,091	-123,417	158,451	-2,711	0	7	4,077	-67	-245	-632	-137	-617	0	17	-79	-11	3,061	-134	-78	-25,126	3,725	-120	-320	-14	-11,189	-3,083	-44	1,011	-135,195	18,638	856	1,102	800	-1,498	342
Cash Flows From Financing Activities:
Cash Flows From Financing Activities:
Proceeds from employees for exercises of stock options
0	792	2,501	3,023	831	5,632	3,039	2,884	1,920	2,426	2,041	925	85	13	2	137	51	0	486	592	404	446	121	98	1,241	606	1,833	185	952	1,225	2,069	1,469	1,054	-	-	-	-
Proceeds from employees, for our remittance to tax authorities, upon vesting of restricted stock
-	-	-	-	-	0	0	0	4,645	0	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Payments to tax authorities upon employees' surrender of restricted stock upon vesting and upon exercises of stock options
-	-	-	-	-	-7	0	0	27,686	2,855	192	411	873	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common stock from stock option exercises
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,281
Purchase of treasury stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-1	0	0	1,652	109	8,631	0	317	-	-	-	-
Purchase and retirement of restricted stock to satisfy employees' tax liability at vesting
-	-	-	-	-	-	-	-	-	-	-	-	-	-	164	273	392	9	114	253	262	1,049	94	590	0	897	202	26	384	942	166	645	-319	-	-	-	-
Repayment of capital leases
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	9	8	8	8	7
Proceeds from revolving line of credit (Note 14)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	25,000	75,000	-	-	-	-	-	-	-	-
Repayment of revolving line of credit (Note 14)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25,000	25,000	50,000	75,000	-	-	-	-	-	-	-	-
Net cash provided by financing activities
0	1,011	2,504	5,281	831	6,007	3,039	3,618	-21,121	-7,226	115,815	920	-788	-9,263	28,640	40,608	-341	283	372	674	142	-312	27	-144	1,241	77,355	-23,369	-17,644	-1,084	-12,767	69,368	4,015	409	-1,156	22,411	1,082	1,274
Effect of exchange rates on cash and equivalents
-86	94	-138	49	-55	-47	-23	-265	-21	46	88	156	26	-138	157	-112	68	-159	168	91	-1,354	130	-1,610	-724	496	-930	-1,121	-44	-140	-	-	-	-	-	-	-	-
Net increase in cash, cash equivalents and restricted cash
5,934	-64,220	6,367	-154,381	119,172	-9,061	-7,830	-9,142	-43,810	-20,145	109,155	1,117	-21,026	-13,383	15,846	23,453	-7,435	3,214	-5,744	18,906	-6,577	-14,292	11,829	14,671	-38,572	84,332	-49,129	-38,970	20,375	-3,585	-46,871	40,781	28,171	10,909	43,244	28,227	-14,735
Targent milestones included in intangible assets and accrued liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-5,159	5,159	5,000
Noncash investing activities:
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	1,652	-	-	-	-	-	-	-	-
Supplemental disclosure of cash flow information:
Cash paid for facility and equipment under operating leases
593	569	345	450	471	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for income taxes
0	0	5	0	33	7	11	27	0	7	0	10	0	0	0	2	9	3	0	1	331	0	0	329	0	-	-	-	-	-	-	-	-	-	-	-	-
C-E MELPHALAN license included in intangible assets and other long term obligations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-3,000	7,700	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	1,179	0	1,513	0	1,650	0	1,650	0	1,650	0	1,650	0	1,639	0	1,588	0	-	-	-	-	-	-	-	-	-	-	-	-
Noncash investing activities:
Additions of property and equipment that remain in accounts payable and other accrued liabilities (Note 3(b))
2,772	-	-2,909	3,209	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Conversion of preferred stock to common stock
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	37